{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:14:53Z","timestamp":1790396093235,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836031008"],"award-info":[{"award-number":["836031008"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["13OI116"],"award-info":[{"award-number":["13OI116"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1007\/s40262-019-00742-8","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T07:30:35Z","timestamp":1550043035000},"page":"859-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-109X","authenticated-orcid":false,"given":"Kioa Lente","family":"Wijnsma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Langemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia E. M.","family":"Schols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena. B.","family":"Volokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F. M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"issue":"12","key":"742_CR1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233\u201343.","journal-title":"N Engl J Med."},{"issue":"6","key":"742_CR2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552\u20139.","journal-title":"N Engl J Med."},{"key":"742_CR3","volume-title":"Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration (FDA)","year":"2007","unstructured":"US Food and Drug Administration (FDA). Clinical pharmacology and biopharmaceutics review. Silver Spring: US FDA; 2007."},{"issue":"1","key":"742_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","volume":"14","author":"D Ricklin","year":"2018","unstructured":"Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26\u201347.","journal-title":"Nat Rev Nephrol."},{"key":"742_CR5","volume-title":"CHMP extension of indication variation assessment report","author":"European Medicines Ageny (EMA)","year":"2017","unstructured":"European Medicines Ageny (EMA). CHMP extension of indication variation assessment report. London: EMA; 2017."},{"issue":"23","key":"742_CR6","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med."},{"issue":"6","key":"742_CR7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00228-016-2027-z","volume":"72","author":"J Castaneda-Sanabria","year":"2016","unstructured":"Castaneda-Sanabria J, Hajage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol. 2016;72(6):737\u201346.","journal-title":"Eur J Clin Pharmacol."},{"issue":"8","key":"742_CR8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/0272989X14539731","volume":"34","author":"D Coyle","year":"2014","unstructured":"Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Mak. 2014;34(8):1016\u201329.","journal-title":"Med Decis Mak."},{"issue":"6","key":"742_CR9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","volume":"7","author":"P Gatault","year":"2015","unstructured":"Gatault P, Brachet G, Ternant D, Degenne D, Recipon G, Barbet C, et al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs. 2015;7(6):1205\u201311.","journal-title":"MAbs."},{"issue":"4","key":"742_CR10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/cpt.686","volume":"102","author":"E Volokhina","year":"2017","unstructured":"Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, et al. Eculizumab dosing regimen in atypical HUS: Possibilities for individualized treatment. Clin Pharmacol Ther. 2017;102(4):671\u20138.","journal-title":"Clin Pharmacol Ther."},{"issue":"4","key":"742_CR11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00277-017-2924-y","volume":"96","author":"F Alashkar","year":"2017","unstructured":"Alashkar F, Vance C, Herich-Terhurne D, Preising N, Duhrsen U, Roth A. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. Ann Hematol. 2017;96(4):589\u201396.","journal-title":"Ann Hematol."},{"issue":"5","key":"742_CR12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","volume":"30","author":"W Hayes","year":"2015","unstructured":"Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol. 2015;30(5):775\u201381.","journal-title":"Pediatr Nephrol."},{"issue":"4","key":"742_CR13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.nefro.2017.10.001","volume":"38","author":"A Oruc","year":"2018","unstructured":"Oruc A, Ayar Y, Vuruskan BA, Yildiz A, Aktas N, Yavuz M, et al. Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia. 2018;38(4):448\u201350.","journal-title":"Nefrologia."},{"key":"742_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-pathol-012615-044145","volume":"12","author":"MK Liszewski","year":"2017","unstructured":"Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement dysregulation and disease: insights from contemporary genetics. Annu Rev Pathol. 2017;12:25\u201352.","journal-title":"Annu Rev Pathol."},{"issue":"4","key":"742_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","volume":"31","author":"AC Baines","year":"2017","unstructured":"Baines AC, Brodsky RA. Complementopathies. Blood Rev. 2017;31(4):213\u201323.","journal-title":"Blood Rev."},{"issue":"4","key":"742_CR16","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840\u20137.","journal-title":"Blood."},{"key":"742_CR17","volume-title":"Summary of product characteristcs","author":"European Medicines Ageny (EMA)","year":"2017","unstructured":"European Medicines Ageny (EMA). Summary of product characteristcs. London: EMA; 2017."},{"issue":"2","key":"742_CR18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","volume":"22","author":"S Jodele","year":"2016","unstructured":"Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):307\u201315.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"742_CR19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643\u201357.","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"742_CR20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","volume":"65","author":"M Le Quintrec","year":"2015","unstructured":"Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis. 2015;65(3):484\u20139.","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"742_CR21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ndt\/gfu317","volume":"31","author":"TD Barbour","year":"2016","unstructured":"Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy. Nephrol Dial Transplant. 2016;31(5):717\u201325.","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"742_CR22","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2215\/CJN.01360215","volume":"10","author":"MJ Oosterveld","year":"2015","unstructured":"Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, et al. Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol. 2015;10(10):1773\u201382.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"742_CR23","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","volume":"37","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249\u201355.","journal-title":"Rheumatol Int."},{"issue":"3","key":"742_CR24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539\u201351.","journal-title":"Kidney Int."},{"issue":"4","key":"742_CR25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","volume":"20","author":"S Jodele","year":"2014","unstructured":"Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20(4):518\u201325.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"742_CR26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","volume":"7","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7(5):748\u201356.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"12","key":"742_CR27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMc1111953","volume":"366","author":"M Vivarelli","year":"2012","unstructured":"Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med. 2012;366(12):1163\u20135.","journal-title":"N Engl J Med."},{"issue":"1","key":"742_CR28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3928\/23258160-20131217-01","volume":"45","author":"CA De Amorim Garcia Filho","year":"2014","unstructured":"De Amorim Garcia Filho CA, Yehoshua Z, Gregori G, Nunes RP, Penha FM, Moshfeghi AA, et al. Change in Drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2014;45(1):18\u201331.","journal-title":"Ophthalmic Surg Lasers Imaging."},{"issue":"3","key":"742_CR29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","volume":"29","author":"Y Delmas","year":"2014","unstructured":"Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant. 2014;29(3):565\u201372.","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"742_CR30","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","volume":"99","author":"FS De Fontbrune","year":"2015","unstructured":"De Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation. 2015;99(9):1953\u20139.","journal-title":"Transplantation."},{"issue":"3","key":"742_CR31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2040620716681748","volume":"8","author":"M Griffin","year":"2017","unstructured":"Griffin M, Munir T. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician\u2019s guide. Ther Adv Hematol. 2017;8(3):119\u201326.","journal-title":"Ther Adv Hematol."},{"issue":"8","key":"742_CR32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","volume":"85","author":"P Hillmen","year":"2010","unstructured":"Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85(8):553\u20139.","journal-title":"Am J Hematol."},{"issue":"1","key":"742_CR33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","volume":"67","author":"CM Nester","year":"2015","unstructured":"Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67(1):31\u201342.","journal-title":"Mol Immunol."},{"issue":"10095","key":"742_CR34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681\u201396.","journal-title":"Lancet."},{"issue":"4","key":"742_CR35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","volume":"36","author":"C Mele","year":"2014","unstructured":"Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol. 2014;36(4):399\u2013420.","journal-title":"Semin Immunopathol."},{"issue":"1","key":"742_CR36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","volume":"48","author":"JF Howard Jr","year":"2013","unstructured":"Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76\u201384.","journal-title":"Muscle Nerve."},{"issue":"4","key":"742_CR37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/21678707.2017.1307104","volume":"5","author":"J Schubert","year":"2017","unstructured":"Schubert J, Menne J. Eculizumab for the treatment of hemolytic paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis. Expert Opin Orphan Drugs. 2017;5(4):375\u20139.","journal-title":"Expert Opin Orphan Drugs."},{"issue":"3","key":"742_CR38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367\u201376.","journal-title":"Drugs."},{"issue":"1","key":"742_CR39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113\u201328.","journal-title":"Ann N Y Acad Sci."},{"issue":"4","key":"742_CR40","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","volume":"124","author":"S Jodele","year":"2014","unstructured":"Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645\u201353.","journal-title":"Blood."},{"key":"742_CR41","volume-title":"Assessment report eculizumab","author":"European Medicines Agency (EMA)","year":"2013","unstructured":"European Medicines Agency (EMA). Assessment report eculizumab. London: EMA; 2013."},{"key":"742_CR42","volume-title":"Soliris: EPAR\u2014scientific discussion","author":"European Medicines Agency (EMA)","year":"2007","unstructured":"European Medicines Agency (EMA). Soliris: EPAR\u2014scientific discussion. London: EMA; 2007."},{"key":"742_CR43","unstructured":"Furie R, Matis L, Rollins S, et al. A single dose, placebo-controlled, double blind, phase I study of the humanized anti-C5 antibody hbG1.1 in patients with systemic lupus erythematosus. Abstract presented at the 64th annual scientific meeting of the American College of Rheumatology, Philadelphia, PA."},{"key":"742_CR44","first-page":"S77","volume":"42","author":"RI Jain","year":"1999","unstructured":"Jain RI, Moreland LW, Caldwell JR, Rollins SA, Mojcik CF. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 1999;42:S77.","journal-title":"Arthritis Rheum."},{"issue":"6","key":"742_CR45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554\u201362.","journal-title":"Lancet Neurol."},{"key":"742_CR46","unstructured":"Takada K, Bookbinders S, Furie R. A pilot study of eculizumab in patients with dermatomyositis. Arthritis Rheum. 2002;46(S489)."},{"issue":"2","key":"742_CR47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2141.2008.07183.x","volume":"142","author":"J Schubert","year":"2008","unstructured":"Schubert J, Hillmen P, Roth A, Young NS, Elebute MO, Szer J, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2008;142(2):263\u201372.","journal-title":"Br J Haematol."},{"issue":"6","key":"742_CR48","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.transproceed.2015.06.029","volume":"47","author":"B Yelken","year":"2015","unstructured":"Yelken B, Arpali E, Gorcin S, Kocak B, Karatas C, Demiralp E, et al. Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience. Transplant Proc. 2015;47(6):1754\u20139.","journal-title":"Transplant Proc."},{"issue":"4","key":"742_CR49","doi-asserted-by":"crossref","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PloS one. 2018;13(4):e0195909.","journal-title":"PloS one."},{"issue":"8","key":"742_CR50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493\u2013507.","journal-title":"Clin Pharmacokinet."},{"issue":"9","key":"742_CR51","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","volume":"13","author":"A Dmytrijuk","year":"2008","unstructured":"Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008;13(9):993\u20131000.","journal-title":"Oncologist."},{"issue":"2","key":"742_CR52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","volume":"187","author":"C Wehling","year":"2017","unstructured":"Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017;187(2):304\u201315.","journal-title":"Clin Exp Immunol."},{"issue":"2","key":"742_CR53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","volume":"160","author":"EB Volokhina","year":"2015","unstructured":"Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol. 2015;160(2):237\u201343.","journal-title":"Clin Immunol."},{"issue":"3","key":"742_CR54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1208\/s12248-017-0183-4","volume":"20","author":"D Yuan","year":"2018","unstructured":"Yuan D, Rode F, Cao Y. A minimal physiologically based pharmacokinetic model with a nested endosome compartment for novel engineered antibodies. AAPS J. 2018;20(3):48.","journal-title":"AAPS J."},{"issue":"5","key":"742_CR55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","volume":"125","author":"RP De Latour","year":"2015","unstructured":"De Latour RP, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775\u201383.","journal-title":"Blood."},{"key":"742_CR56","volume-title":"Approval package aHUS","author":"US Food and Drug Administration (FDA)","year":"2011","unstructured":"US Food and Drug Administration (FDA). Approval package aHUS. US FDA: Silver Spring; 2011."},{"issue":"1","key":"742_CR57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62\u201373.","journal-title":"Br J Haematol."},{"key":"742_CR58","volume-title":"Prescribing information.","author":"US Food and Drug Administration (FDA)","year":"2017","unstructured":"US Food and Drug Administration (FDA). Prescribing information. Silver Spring: US FDA; 2017."},{"issue":"9","key":"742_CR59","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/pbc.25068","volume":"61","author":"UM Reiss","year":"2014","unstructured":"Reiss UM, Schwartz J, Sakamoto KM, Puthenveetil G, Ogawa M, Bedrosian CL, et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer. 2014;61(9):1544\u201350.","journal-title":"Pediatr Blood Cancer."},{"issue":"3","key":"742_CR60","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701\u201311.","journal-title":"Kidney Int."},{"key":"742_CR61","volume-title":"CHMP variation assessment report Type II variation. EMEA\/H\/C\/000791\/II\/0027","author":"European Medicines Agency (EMA)","year":"2011","unstructured":"European Medicines Agency (EMA). CHMP variation assessment report Type II variation. EMEA\/H\/C\/000791\/II\/0027. London: EMA; 2011."},{"issue":"2","key":"742_CR62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","volume":"16","author":"AM Fitzpatrick","year":"2011","unstructured":"Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16(2):84\u201391.","journal-title":"J Peripher Nerv Syst."},{"issue":"3","key":"742_CR63","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ajh.24280","volume":"91","author":"P Hillmen","year":"2016","unstructured":"Hillmen P, Muus P, Szer J, Hill A, Hochsmann B, Kulasekararaj A, et al. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2016;91(3):E16\u20137.","journal-title":"Am J Hematol."},{"issue":"4","key":"742_CR64","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MBC.0000000000000248","volume":"26","author":"MC Vekemans","year":"2015","unstructured":"Vekemans MC, Lambert C, Ferrant A, Saussoy P, Havelange V, Debieve F, et al. Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab. Blood Coagul Fibrinol. 2015;26(4):464\u20136.","journal-title":"Blood Coagul Fibrinol."},{"issue":"1","key":"742_CR65","first-page":"36","volume":"4","author":"R Sharma","year":"2015","unstructured":"Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep. 2015;4(1):36\u20138.","journal-title":"Leuk Res Rep."},{"issue":"Suppl 1","key":"742_CR66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nep.12938","volume":"22","author":"R Gately","year":"2017","unstructured":"Gately R, San A, Kurtkoti J, Parnham A. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab. Nephrology (Carlton). 2017;22(Suppl 1):32\u20135.","journal-title":"Nephrology (Carlton)."},{"issue":"2 Part 2","key":"742_CR67","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","volume":"122","author":"G Ardissino","year":"2013","unstructured":"Ardissino G, Ossola MW, Baffero GM, Rigotti A, Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol. 2013;122(2 Part 2):487\u20139.","journal-title":"Obstet Gynecol."},{"issue":"3","key":"742_CR68","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08099.x","volume":"149","author":"R Kelly","year":"2010","unstructured":"Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149(3):446\u201350.","journal-title":"Br J Haematol."},{"issue":"12","key":"742_CR69","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","volume":"31","author":"A Servais","year":"2016","unstructured":"Servais A, Devillard N, Fremeaux-Bacchi V, Hummel A, Salomon L, Contin-Bordes C, et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant. 2016;31(12):2122\u201330.","journal-title":"Nephrol Dial Transplant."},{"issue":"11","key":"742_CR70","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","volume":"373","author":"RJ Kelly","year":"2015","unstructured":"Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032\u20139.","journal-title":"N Engl J Med."},{"key":"742_CR71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jim.2018.06.010","volume":"460","author":"MAV Willrich","year":"2018","unstructured":"Willrich MAV, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, et al. The impact of eculizumab on routine complement assays. J Immunol Methods. 2018;460:63\u201371.","journal-title":"J Immunol Methods."},{"key":"742_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2017.06.007","volume":"183","author":"B Puissant-Lubrano","year":"2017","unstructured":"Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, Chauveau D, Decramer S, Garnier A, et al. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. Clin Immunol. 2017;183:1\u20137.","journal-title":"Clin Immunol."},{"key":"742_CR73","volume-title":"Pharmacometrics review","author":"US Food and Drug Administration (FDA)","year":"2007","unstructured":"US Food and Drug Administration (FDA). Pharmacometrics review. Silver Spring: US FDA; 2007."},{"issue":"3","key":"742_CR74","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2010.08096.x","volume":"149","author":"A Hill","year":"2010","unstructured":"Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;149(3):414\u201325.","journal-title":"Br J Haematol."},{"issue":"5","key":"742_CR75","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061\u201373.","journal-title":"Kidney Int."},{"issue":"8","key":"742_CR76","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","volume":"129","author":"MJ Harder","year":"2017","unstructured":"Harder MJ, Kuhn N, Schrezenmeier H, Hochsmann B, Von Zabern I, Weinstock C, et al. Incomplete inhibition by eculizumab: Mechanistic evidence for residual C5 activity during strong complement activation. Blood. 2017;129(8):970\u201380.","journal-title":"Blood."},{"issue":"1","key":"742_CR77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-017-0496-x","volume":"10","author":"M Sica","year":"2017","unstructured":"Sica M, Rondelli T, Ricci P, De Angioletti M, Risitano AM, Notaro R. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes. J Hematol Oncol. 2017;10(1):126.","journal-title":"J Hematol Oncol."},{"issue":"7","key":"742_CR78","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"JI Nishimura","year":"2014","unstructured":"Nishimura JI, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632\u20139.","journal-title":"N Engl J Med."},{"issue":"4","key":"742_CR79","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/ijlh.12512","volume":"38","author":"Y Du","year":"2016","unstructured":"Du Y, Zhang Q, Han B. Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria. Int J Lab Hematol. 2016;38(4):e84\u20135.","journal-title":"Int J Lab Hematol."},{"issue":"1","key":"742_CR80","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","volume":"197","author":"JA Schatz-Jakobsen","year":"2016","unstructured":"Schatz-Jakobsen JA, Zhang Y, Johnson K, Neill A, Sheridan D, Andersen GR. Structural basis for eculizumab-mediated inhibition of the complement terminal pathway. J Immunol. 2016;197(1):337\u201344.","journal-title":"J Immunol."},{"key":"742_CR81","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx196","author":"KL Wijnsma","year":"2017","unstructured":"Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar N, Wetzels JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant. 2017. https:\/\/doi.org\/10.1093\/ndt\/gfx196(Epub 4 Jul 2017).","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"742_CR82","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","volume":"66","author":"G Ardissino","year":"2015","unstructured":"Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015;66(1):172\u20133.","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"742_CR83","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00467-017-3813-2","volume":"33","author":"G Ardissino","year":"2018","unstructured":"Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018;33(3):457\u201361.","journal-title":"Pediatr Nephrol."},{"key":"742_CR84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805","author":"AG Kulasekararaj","year":"2018","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2018. https:\/\/doi.org\/10.1182\/blood-2018-09-876805(Epub 3 Dec 2018).","journal-title":"Blood."},{"key":"742_CR85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136","author":"JW Lee","year":"2018","unstructured":"Lee JW, de Sicre de Fontbrune F, Lee LWL, Pessoa V, Gualandro S, Fureder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2018. https:\/\/doi.org\/10.1182\/blood-2018-09-876136(Epub 3 Dec 2018).","journal-title":"Blood."},{"issue":"10","key":"742_CR86","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.12864","volume":"45","author":"A Mallett","year":"2015","unstructured":"Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J. 2015;45(10):1054\u201365.","journal-title":"Intern Med J."},{"issue":"1","key":"742_CR87","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Provot F, Delmas Y, Barbet C, Chatelet V, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12(1):50\u20139. https:\/\/doi.org\/10.2215\/CJN.06440616.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"742_CR88","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.transci.2016.09.017","volume":"55","author":"F Gediz","year":"2016","unstructured":"Gediz F, Payzin BK, Ecemis S, Guler N, Yilmaz AF, Topcugil F, et al. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey. Transfus Apher Sci. 2016;55(3):357\u201362.","journal-title":"Transfus Apher Sci."},{"issue":"2","key":"742_CR89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-015-1142-y","volume":"20","author":"N Ito","year":"2016","unstructured":"Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, et al. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20(2):265\u201372.","journal-title":"Clin Exp Nephrol."},{"issue":"1","key":"742_CR90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"JV Walle","year":"2017","unstructured":"Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30(1):127\u201334.","journal-title":"J Nephrol."},{"issue":"3","key":"742_CR91","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jth.12764","volume":"13","author":"M Cugno","year":"2015","unstructured":"Cugno M, Tedeschi S, Ardissino G. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment. J Thromb Haemost. 2015;13(3):485\u20136.","journal-title":"J Thromb Haemost."},{"issue":"9","key":"742_CR92","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.12639","volume":"12","author":"C Wehling","year":"2014","unstructured":"Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost. 2014;12(9):1437\u20139.","journal-title":"J Thromb Haemost."},{"issue":"12","key":"742_CR93","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","volume":"110","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123\u20138.","journal-title":"Blood."},{"issue":"7","key":"742_CR94","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","volume":"106","author":"A Hill","year":"2005","unstructured":"Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(7):2559\u201365.","journal-title":"Blood."},{"issue":"25","key":"742_CR95","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival. Blood. 2011;117(25):6786\u201392.","journal-title":"Blood."},{"issue":"6","key":"742_CR96","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12185-011-0867-y","volume":"93","author":"A Roth","year":"2011","unstructured":"Roth A, Hock C, Konik A, Christoph S, Duhrsen U. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: Safety, efficacy, and unexpected laboratory phenomena. Int J Hematol. 2011;93(6):704\u201314.","journal-title":"Int J Hematol."},{"issue":"5","key":"742_CR97","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12185-016-2065-4","volume":"104","author":"H Ninomiya","year":"2016","unstructured":"Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104(5):548\u201358.","journal-title":"Int J Hematol."},{"key":"742_CR98","volume-title":"Pharmacology and toxicology review and evaluation","author":"US Food and Drug Administration (FDA)","year":"2006","unstructured":"US Food and Drug Administration (FDA). Pharmacology and toxicology review and evaluation. Silver Spring: US FDA; 2006."},{"issue":"12","key":"742_CR99","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol."},{"issue":"10","key":"742_CR100","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","volume":"27","author":"JT Kielstein","year":"2012","unstructured":"Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 2012;27(10):3807\u201315.","journal-title":"Nephrol Dial Transplant."},{"issue":"11","key":"742_CR101","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","volume":"11","author":"MD Stegall","year":"2011","unstructured":"Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11(11):2405\u201313.","journal-title":"Am J Transplant."},{"issue":"3","key":"742_CR102","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","volume":"121","author":"Z Yehoshua","year":"2014","unstructured":"Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121(3):693\u2013701.","journal-title":"Ophthalmology."},{"issue":"1","key":"742_CR103","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","volume":"22","author":"AI Davidson","year":"2017","unstructured":"Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, et al. Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017;22(1):4\u201312.","journal-title":"J Peripher Nerv Syst."},{"issue":"5","key":"742_CR104","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ana.24770","volume":"80","author":"D Mevorach","year":"2016","unstructured":"Mevorach D, Reiner I, Grau A, Ilan U, Berkun Y, Ta-Shma A, et al. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. Ann Neurol. 2016;80(5):708\u201317.","journal-title":"Ann Neurol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00742-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T20:17:28Z","timestamp":1662927448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00742-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":104,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00742-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"13 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by grants from ZonMw \u2018Goed Gebruik Geneesmiddelen\u2019 (Project number 836031008) and the Dutch Kidney Foundation (13OI116). These organizations did not have any role in drafting this manuscript or the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Nicole C.A.J. van de Kar and Prof. Dr. Jack F.M. Wetzels are both members of the international advisory board of Alexion, and Prof. Dr. Jack F.M. Wetzels also received a grant from Alexion. Roger J. Br\u00fcggemann has served as a consultant to Astellas Pharma, Inc., F2G, Gilead Sciences, Merck Sharpe and Dome Corp., and Pfizer, Inc., and has received unrestricted research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharpe and Dome Corp., and Pfizer, Inc. All contracts were through Radboud University Medical Center (Radboudumc) and all payments were invoiced by Radboudumc. Kioa L. Wijnsma, Rob ter Heine, Dirk Jan A.R Moes, Saskia Langemeijer, Saskia E.M. Schols, Elena B. Volokhina and Lambertus P. van den Heuvel have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}